Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Escitalopram in Asthma Patients With Frequent Exacerbation
NCT06216535Phase 2Recruiting
- Sponsor
- UT Southwestern Medical Center
- Start
- May 2025
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Escitalopram oxalate oral solution in asthma (2 arms), sponsored by UT Southwestern Medical Center. Primary endpoint: Total number of severe asthma exacerbations at 24 weeks. Started May 2025; status: recruiting.
02
Drugs
Escitalopram oxalate oral solution
03
Conditions
asthma
Beyond the preview
Go deeper on NCT06216535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06216535.